Trillium Therapeutics Stock Forecast, Price & News

+0.14 (+1.37 %)
(As of 04/15/2021 12:00 AM ET)
Today's Range
Now: $10.38
50-Day Range
MA: $10.79
52-Week Range
Now: $10.38
Volume861,049 shs
Average Volume1.32 million shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.
Trillium Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TRIL
Phone(416) 595-0627
Year FoundedN/A



Sales & Book Value

Annual Sales$120,000.00
Book Value($0.86) per share


Net Income$-41,620,000.00


Market Cap$1.07 billion
Next Earnings Date5/21/2021 (Estimated)


Trillium Therapeutics (NASDAQ:TRIL) Shares Down 5.5%
April 9, 2021 |
These 3 Stocks Will Make You A Fortune If They Succeed
April 1, 2021 |
TSX Fades to End March, Q1
March 31, 2021 |
Warren Buffett: His Advice on Market Crashes
March 5, 2021 |
TSX:TRIL (Trillium Therapeutics Inc.)
January 7, 2021 |
My Favorite Biotech Stock for 2021
January 4, 2021 |
The Worst Mistake Trillium Investors Can Make Right Now
January 4, 2021 |
How Did Trillium Stock Perform in 2020?
December 8, 2020 |
Trillium Therapeutics Inc Buy
November 18, 2020 |
Trillium Therapeutics Inc Outperform
October 14, 2020 |
Stocks in play: Trillium Therapeutics Inc.
October 8, 2020 |
See More Headlines


Overall MarketRank

1.72 out of 5 stars

Medical Sector

211th out of 2,021 stocks

Pharmaceutical Preparations Industry

95th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.14 (+1.37 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TRIL News and Ratings via Email

Sign-up to receive the latest news and ratings for TRIL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Trillium Therapeutics (NASDAQ:TRIL) Frequently Asked Questions

Is Trillium Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Trillium Therapeutics stock.
View analyst ratings for Trillium Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Trillium Therapeutics?

Wall Street analysts have given Trillium Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Trillium Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Trillium Therapeutics' next earnings date?

Trillium Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Trillium Therapeutics

How were Trillium Therapeutics' earnings last quarter?

Trillium Therapeutics Inc. (NASDAQ:TRIL) issued its quarterly earnings data on Thursday, March, 18th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.11. The biotechnology company earned $0.03 million during the quarter.
View Trillium Therapeutics' earnings history

How has Trillium Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Trillium Therapeutics' stock was trading at $5.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRIL stock has increased by 100.0% and is now trading at $10.38.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TRIL?

7 equities research analysts have issued twelve-month target prices for Trillium Therapeutics' shares. Their forecasts range from $14.00 to $28.00. On average, they anticipate Trillium Therapeutics' stock price to reach $21.83 in the next twelve months. This suggests a possible upside of 110.3% from the stock's current price.
View analysts' price targets for Trillium Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Trillium Therapeutics' key executives?

Trillium Therapeutics' management team includes the following people:
  • Jan Skvarka, President, Chief Executive Officer & Director
  • James T. Parsons, Chief Financial Officer
  • Robert A. Uger, Chief Scientific Officer
  • Ingmar Bruns, Chief Medical Officer
  • Penka Petrova, Chief Development Officer

Who are some of Trillium Therapeutics' key competitors?

What other stocks do shareholders of Trillium Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trillium Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Energy Transfer (ET), Gilead Sciences (GILD), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Actinium Pharmaceuticals (ATNM) and Evoke Pharma (EVOK).

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the NASDAQ under the ticker symbol "TRIL."

Who are Trillium Therapeutics' major shareholders?

Trillium Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.04%). Company insiders that own Trillium Therapeutics stock include James T Parsons, Jan Skvarka, Penka Petrova and Robert Uger.
View institutional ownership trends for Trillium Therapeutics

Which institutional investors are selling Trillium Therapeutics stock?

TRIL stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have sold Trillium Therapeutics company stock in the last year include James T Parsons, Jan Skvarka, Penka Petrova, and Robert Uger.
View insider buying and selling activity for Trillium Therapeutics
or view top insider-selling stocks.

How do I buy shares of Trillium Therapeutics?

Shares of TRIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trillium Therapeutics' stock price today?

One share of TRIL stock can currently be purchased for approximately $10.38.

How much money does Trillium Therapeutics make?

Trillium Therapeutics has a market capitalization of $1.07 billion and generates $120,000.00 in revenue each year. The biotechnology company earns $-41,620,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

What is Trillium Therapeutics' official website?

The official website for Trillium Therapeutics is

Where are Trillium Therapeutics' headquarters?

Trillium Therapeutics is headquartered at 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9.

How can I contact Trillium Therapeutics?

Trillium Therapeutics' mailing address is 2488 DUNWIN DRIVE, MISSISSAUGA A6, L5L 1J9. The biotechnology company can be reached via phone at (416) 595-0627 or via email at [email protected]

This page was last updated on 4/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.